Reply
Annalisa Berzigotti, Jaime Bosch, on behalf of the Spordiet Study Investigators – 22 January 2018
Pyrroloquinoline quinone prevents developmental programming of microbial dysbiosis and macrophage polarization to attenuate liver fibrosis in offspring of obese mice
Jacob E. Friedman, Evgenia Dobrinskikh, Alba Alfonso‐Garcia, Alexander Fast, Rachel C. Janssen, Taylor K. Soderborg, Aimee L. Anderson, Julie A. Reisz, Angelo D'Alessandro, Daniel N. Frank, Charles E. Robertson, Becky A. de la Houssaye, Linda K. Johnson, David J. Orlicky, Xiaoxin X. Wang, Moshe Levi, Eric O. Potma, Karim C. El Kasmi, Karen R.
Balancing exercise‐induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis
Amritpal Dhaliwal, Jenny Towey, Geoffrey Haydon, Ahmed M. Elsharkawy, Matthew J. Armstrong – 22 January 2018
Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D?
Silvia Martini, Lucio Caccamo, Mario Rizzetto – 21 January 2018
Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials
Cyrielle Caussy, Scott B. Reeder, Claude B. Sirlin, Rohit Loomba – 21 January 2018 – Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration–approved therapies for treating NASH.
Placental growth factor: New treatment target bringing hope for hepatopulmonary syndrome
Mercedes Fernandez – 21 January 2018
Cryopreserved neonatal hepatocytes may be a source for transplantation: Evaluation of functionality toward clinical use
Charlotte A. Lee, Anil Dhawan, Valeria Iansante, Sharon Lehec, Shirin E. Khorsandi, Celine Filippi, Simon Walker, Raquel Fernandez‐Dacosta, Nigel Heaton, Sanjay Bansal, Ragai R. Mitry, Emer Fitzpatrick – 21 January 2018 – Neonatal livers are a potential source of good‐quality hepatocytes for clinical transplantation. We compared viability and function of neonatal hepatocytes (NHs) and adult hepatocytes (AHs) and report their clinical use both intraportally and in alginate microbeads.
Reply
Minjong Lee, Jeong‐Hoon Lee – 21 January 2018
Basolateral CD147 induces hepatocyte polarity loss by E‐cadherin ubiquitination and degradation in hepatocellular carcinoma progress
Meng Lu, Jiao Wu, Zhi‐Wei Hao, Yu‐Kui Shang, Jing Xu, Gang Nan, Xia Li, Zhi‐Nan Chen, Huijie Bian – 21 January 2018 – Hepatocytes are epithelial cells with highly specialized polarity. The disorder and loss of hepatocyte polarity leads to a weakness of cell adhesion and connection, the induction of epithelial–mesenchymal transition, and eventually the occurrence of hepatocellular carcinoma (HCC). Cluster of differentiation 147 (CD147), a tumor‐related glycoprotein, promotes epithelial–mesenchymal transition and the invasion of HCC.
Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials
Cyrielle Caussy, Scott B. Reeder, Claude B. Sirlin, Rohit Loomba – 21 January 2018 – Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration–approved therapies for treating NASH.